Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hemay005 in moderate to severe COPD
NCT07314242Phase 2Not yet recruiting
- Sponsor
- Hemay Pharmaceutical Technology
- Start
- Jan 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of mufemilast in chronic obstructive pulmonary disease (COPD), sponsored by Hemay Pharmaceutical Technology. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
mufemilast
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT07314242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07314242.